BridgeBio Pharma Shares Rise 14% on Expected Results from Heart-Disease Study

Shares of BridgeBio Pharma climbed 14% to $20.85 in after-hours Friday trading after the company said it would share results from the latest phase of its transthyretin amyloid cardiomyopathy heart disease study.